Acadia Pharmaceuticals
ACAD · Pharmaceuticals
$19.73
2.9%Indivior
INDV · Pharmaceuticals
$34.47
2.4%The short version
- Indivior is the larger business, with $1.2B of revenue in fiscal 2025 against $1.1B for Acadia Pharmaceuticals.
- Acadia Pharmaceuticals grew revenue faster (11.9%, against 4.3%).
- Indivior kept more of each dollar of sales as operating profit (21.2% operating margin, against 9.8% operating margin).
- Acadia Pharmaceuticals turned more of its sales into free cash flow (9.8% FCF margin, against −7.5% FCF margin).
- Investors pay more for each dollar of Indivior’s earnings: a P/E of 12.4x against 8.8x for Acadia Pharmaceuticals.
| Latest fiscal year | ACAD · FY25 | INDV · FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.4B | $4.3B |
| Revenue | $1.1B | $1.2B |
| Free cash flow | $105M | −$93.0M |
| Net income | $391M | $210M |
| Growth | ||
| Revenue growth | 11.9% | 4.3% |
| 5-year growth | 19.4% | — |
| Share count change | 2.1% | −3.8% |
| Profitability | ||
| Gross margin | 91.7% | 80.2% |
| Operating margin | 9.8% | 21.2% |
| Net margin | 36.5% | 17.0% |
| FCF margin | 9.8% | −7.5% |
| Return on capital | — | — |
| Return on equity | 39.9% | — |
| Balance sheet | ||
| Net debt | — | $124M |
| Net debt / EBITDA | — | 0.5x |
| Dividends and buybacks | $0.0M | $11.0M |
| Valuation & quality | ||
| P/E | 8.8x | 12.4x |
| Piotroski F-score | — | 4 |
FY16
ACAD $17.3M
INDV —
FY17
ACAD $125M
INDV —
FY18
ACAD $224M
INDV —
FY19
ACAD $339M
INDV —
FY20
ACAD $442M
INDV —
FY21
ACAD $484M
INDV $791M
FY22
ACAD $517M
INDV $901M
FY23
ACAD $726M
INDV $1.1B
FY24
ACAD $958M
INDV $1.2B
FY25
ACAD $1.1B
INDV $1.2B
ACAD
INDV
FY16
ACAD −1,574.1%
INDV —
FY17
ACAD −234.1%
INDV —
FY18
ACAD −110.6%
INDV —
FY19
ACAD −72.7%
INDV —
FY20
ACAD −64.9%
INDV —
FY21
ACAD −35.2%
INDV 26.9%
FY22
ACAD −43.2%
INDV −9.0%
FY23
ACAD −10.1%
INDV −13.9%
FY24
ACAD 24.1%
INDV 3.2%
FY25
ACAD 9.8%
INDV 21.2%
ACAD
INDV
FY16
ACAD −$210M
INDV —
FY17
ACAD −$219M
INDV —
FY18
ACAD −$170M
INDV —
FY19
ACAD −$152M
INDV —
FY20
ACAD −$144M
INDV —
FY21
ACAD −$127M
INDV $349M
FY22
ACAD −$114M
INDV −$9.0M
FY23
ACAD $16.7M
INDV −$308M
FY24
ACAD $157M
INDV $7.0M
FY25
ACAD $105M
INDV −$93.0M
ACAD
INDV
FY16
ACAD —
INDV —
FY17
ACAD —
INDV —
FY18
ACAD —
INDV —
FY19
ACAD —
INDV —
FY20
ACAD —
INDV —
FY21
ACAD —
INDV —
FY22
ACAD —
INDV —
FY23
ACAD —
INDV —
FY24
ACAD —
INDV —
FY25
ACAD —
INDV —
ACAD
INDV
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.